Clinical Trial Update: A Clinical Study to Test How Effective and Safe GLPG1690 is for Participants With Systemic Sclerosis [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the safety and effectiveness of GLPG1690 in systemic sclerosis has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Sclerosis

Drugs mentioned

• GLPG1690 (GLPG1690)

Snippet

Sponsor: Galapagos NV | Conditions: Systemic Sclerosis | Phase 2 | Status: COMPLETED | Results posted: 2021-05-04